1163P Impact of brain metastases in synchronous single organ oligometastatic lung cancer (OMD)

Abstract

Local radical therapy (LRT) improves survival in oligometastatic non-small cell lung cancer (OMD) patients. The scientific evidence on re-treatments and the role of brain involvement during the course of disease is scarce. We therefore performed a retrospective analysis to evaluate follow-up therapies after LRT and to describe predictors of survival. 106 patients with synchronous, single organ OMD with ≤3 metastases from one certified North-German lung cancer center were included and analyzed. All underwent thorough initial staging with PET scan, brain imaging (CT or MRT) and mediastinal staging. 106 patients were included (median age 67 [37–89], adenocarcinoma 66% (n=70), male 60% (n=64), ECOG 0 and 1 83% (n=88), current or ex heavy smoker 90% (n=95)). 27% had brain (n=29), 8% liver (n=8), 62% other extracranial metastases (n=66) and one patient had no metastases. The OS was 11 months for all patients. Patients who receive LRT (n=67) have a significantly longer OS than patients without (n=39) (13 months vs. 8 months, p<0.006). LRT for every relapse was possible for 48% of all patients (n=15/31) and more likely in patients with brain metastases (60 vs. 40%). 92% (n=33/36) of all patients with brain metastases (including relapse) have received a LRT. Repeated LRT (n=9/36) resulted in numerically longer OS (21 months vs. 11. months; p<0.419) Use of repeated LRT in relapsed synchronous single organ OMD results in a long-term favorable outcome. Brain control is crucial and determines survival. More cases and detailed data will be presented at the meeting.